For your morning coffee: enjoy our latest newsletter. https://lnkd.in/eNp3SrNm Subscribe and be the first to know: https://lnkd.in/epdwcpnu
V-Bio Ventures
Venture Capital and Private Equity Principals
Sint-Denijs-Westrem (Gent), Flanders 3,131 followers
We empower life sciences innovation by finding, building and financing European start-ups and early-stage companies.
About us
V-Bio Ventures is a venture capital fund that finds, builds and finances young, innovative companies in the life sciences arena. Our fund works closely with Belgium-based VIB, one of the world’s premier life science institutes. We invest throughout Europe in start-up and early-stage companies with high growth potential. We focus on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.
- Website
-
http://www.v-bio.ventures
External link for V-Bio Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- Sint-Denijs-Westrem (Gent), Flanders
- Type
- Partnership
- Founded
- 2015
Locations
-
Primary
Get directions
Pieter van Reysschootlaan 2
104
Sint-Denijs-Westrem (Gent), Flanders 9051, BE
Employees at V-Bio Ventures
Updates
-
🤝 VC and founders work closely together and need to have a strong trusting relationship to get the most out of this partnership and ensure success - read the thoughts of Charles Margarit, PhD in V-Bio Ventures' latest contribution to the BioVox newsletter. https://lnkd.in/ekt29rtj #VentureCapital #Innovation #entrepreneurship #founder #ondernemen
-
Wonderful news to start the day! V-Bio Ventures portfolio company Confo Therapeutics announces its € 60 million Series B to continue building a GPCR powerhouse focused on rare and metabolic diseases. A warm welcome to the new investors.
-
📢 Our portfolio company Precirix, a leader in the development of precision radiopharmaceuticals using camelid single-domain antibodies as targeting vectors announces a partnership with Orchestra Life Sciences to enhance the availability and application of Pb-212, a promising radioisotope for targeted alpha therapy (TAT) for cancer treatment. full press release: https://lnkd.in/epF2AENt #LifeScienceVC #LifeSciences #VentureCapital #Innovation #Biotechnology #oncology #cancercare #cancer #radiopharmaceuticals #cancertreatment #oncologyresearch #RT #radiotherapy #radiationoncology
Exciting News at Precirix! We are partnering with Orchestra Life Sciences to enhance the availability and application of Pb-212, a promising radioisotope in the field of targeted alpha therapy (TAT) for cancer treatment. Click the link below for the full press release: https://lnkd.in/gD3ChkDw
-
-
📢 Our portfolio company Protealis, a pioneer in the breeding of high yield, high protein soy varieties adapted to Northern Europe, has appointed Frank van Lierde as independent member of its board of directors. His extensive experience in the food and bio-industrial sectors brings invaluable expertise to Protealis as the company expands its commercial footprint Welcome on board Frank van Lierde! Press release here: https://lnkd.in/eS_Da48i #biotech #agribusiness #Sustainability #agriculture #shapingthefuture
🗞️ Press news: @Frank van Lierde Joins Protealis’ Board of Directors 👉 https://lnkd.in/eXeyECev #TeamProtealis #NewBoardMember #Commercialization #SustainableSoy
-
-
Exciting news from our portfolio company Augustine. Congrats to the entire team!
Wonderful start of the day: our portfolio company Augustine Therapeutics announces the first closing of its Series A, welcoming Asabys Partners and Eli Lilly and Company as new investors. And congratulations Gerhard Koenig for becoming executive chairman.
-
-
Wonderful start of the day: our portfolio company Augustine Therapeutics announces the first closing of its Series A, welcoming Asabys Partners and Eli Lilly and Company as new investors. And congratulations Gerhard Koenig for becoming executive chairman.
-
-
Great news from a company that has all the ingredients to help patients with both neuromuscular and cardiometabolic disease. Looking forward to the next leg on this exciting journey.
NEWS ALERT! 📢 We are excited to announce the completion of a €17 million ($18.5 million) Series A first close to advance our differentiated HDAC6 inhibitor pipeline to the clinic and support expansion of our R&D and management team. This funding round is led by Asabys Partners, with the participation of Eli Lilly and Company and the US CMT Research Foundation, alongside continued support from our historical investors PMV, AdBio partners, V-Bio Ventures, VIB and GEMMA FRISIUS - FONDS K.U.LEUVEN. As part of this milestone, we welcome Clara Campàs Moya, Managing Partner and co-founder of Asabys Partners, to the Augustine Board of Director, and announce the appointment of Gerhard Koenig as executive Chairman. Stay tuned 🔊 for further updates as we prepare to transition into the clinic with our lead program! To learn more, read the full press release here: https://lnkd.in/eVtvQUdv #AugustineTx #SeriesA #CMT
-
-
De Tijd highlight vandaag een mijlpaal voor AstriVax: een nieuwe vaccintechnologie wordt voor het eerst getest in de mens. Technologisch hoosdtBdje van Belgische makelij.
Het Leuvense AstriVax, dat steun krijgt van onder andere de Bill & Melinda Gates Foundation, heeft de eerste mensen geïnjecteerd met zijn vaccins die een nieuwe technologie gebruiken. CEO Hanne Callewaert: ‘Ik denk dat we heel mooie dingen kunnen realiseren’.
Leuvenaars testen experimenteel vaccin bij honderd Belgen
tijd.be
-
We are thrilled to announce that our portfolio company, AstriVax, has officially entered the clinical stage and has commenced dosing in healthy volunteers! 👏 Achieving this milestone is a testament to the dedication, hard work, and innovative spirit of the Astrivax team. We are proud to support such a pioneering company that is developing vaccines targeting viral infections such as Hepatitis B and HPV. Congratulations to CEO Hanne Callewaert and the entire AstriVax team for reaching this exciting phase! Full press release: https://lnkd.in/d5ADh5R6 #ClinicalTrials #Biotech #Pharma ##LifeScienceVC #LifeSciences
Excited to announce that our company moves into clinical phase with our cutting-edge technology! The first participants have been dosed in ‘SAFYR’, a Phase I clinical study to test the safety and efficacy of AstriVax's technology in close to a 100 healthy adults. The first-in-human safety and immunogenicity data generated by this study will be a stepping stone in advancing AstriVax immunotherapies to treat chronic Hepatitis B and human papillomavirus (HPV) infections. #clinical stage #team #biotech #vaccines #infectious diseases #immunotherapies https://lnkd.in/d5ADh5R6